Literature DB >> 17545561

Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.

M-Y Hsieh1, C-Y Dai, L-P Lee, J-F Huang, W-C Tsai, N-J Hou, Z-Y Lin, S-C Chen, L-Y Wang, W-Y Chang, W-L Chuang, M-L Yu.   

Abstract

AIMS: Positive serum antinuclear antibody (ANA) is present in a number of patients with chronic hepatitis C virus (HCV) infection. This study aimed to evaluate the prevalence of ANA in patients with chronic hepatitis C (CHC) and to elucidate its clinical implications in virological and histological characteristics of CHC infection.
METHODS: A total of 614 CHC patients were enrolled in this prospective, hospital-based study. The serum levels of aspartate aminotransferase, alanine aminotransferase and ANA, and HCV genotype, HCV RNA level, and histological activity index scores for liver histopathology, were determined.
RESULTS: The prevalence of positive ANA (titre >1:40) was 35.0%. Women had a significantly higher prevalence than men (41.2 vs 31.0%; p = 0.012). Patients positive for ANA were significantly older (mean (SD), 53.7 (10.5) vs 49.7 (11.3) years; p<0.001) and had higher mean (SD) alanine aminotransferase levels (186.9 (178.8) vs 155.50 (113.5) IU/l; p<0.001) and lower mean (SD) HCV RNA levels (5.2 (0.9) vs 5.4 (1.0) log IU/ml; p = 0.048) than those without ANA. Among 447 patients undergoing liver biopsy, those positive for ANA had a significantly higher mean (SD) fibrosis score (2.0 (1.3) vs 1.5 (1.1); p<0.001) and a higher frequency of F3-4 (69/187, 36.9% vs 50/260, 19.2%; p<0.001) than those negative for ANA. Multivariate logistic regression analyses showed that advanced fibrosis, lower HCV RNA levels and age were significant factors related to positive ANA.
CONCLUSION: ANA is associated with a more advanced liver fibrosis and lower serum HCV RNA level in patients with CHC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545561     DOI: 10.1136/jcp.2006.046276

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

Review 1.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis.

Authors:  Brian B Borg; Anil Seetharam; Vijay Subramanian; Haseeb Ilias Basha; Mauricio Lisker-Melman; Kevin Korenblat; Christopher D Anderson; Surendra Shenoy; William C Chapman; Jeffrey S Crippin; Thalachallour Mohanakumar
Journal:  Liver Transpl       Date:  2011-07       Impact factor: 5.799

3.  Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.

Authors:  Jee-Fu Huang; Chao-Kuan Huang; Ming-Lung Yu; Chia-Yen Dai; Chung-Feng Huang; Wei-Wen Hung; Ming-Lun Yeh; Meng-Hsuan Hsieh; Jeng-Fu Yang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Chern Chen; Shun-Sheng Wu; Wan-Long Chuang
Journal:  Hepatol Int       Date:  2011-08-18       Impact factor: 6.047

4.  Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.

Authors:  Chung-Feng Huang; Ming-Yen Hsieh; Jeng-Fu Yang; Wu-Cheng Chen; Ming-Lun Yeh; Ching-I Huang; Chia-Yen Dai; Ming-Lung Yu; Zu-Yau Lin; Shinn-Chern Chen; Wan-Long Chuang; Jee-Fu Huang
Journal:  Hepatol Int       Date:  2010-08-04       Impact factor: 6.047

5.  Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy.

Authors:  Chun-Hao Chen; Jee-Fu Huang; Chung-Feng Huang; Ming-Lun Yeh; Jeng-Fu Yang; Ming-Yen Hsieh; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wan-Long Chuang; Chia-Yen Dai; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2012-07-07       Impact factor: 6.047

6.  Autoantibodies in Chinese patients with chronic hepatitis B: prevalence and clinical associations.

Authors:  Bo-An Li; Jia Liu; Jun Hou; Jie Tang; Jian Zhang; Jun Xu; Yong-Ji Song; Ai-Xia Liu; Jing Zhao; Jing-Xia Guo; Lin Chen; Han Wang; Li-Hua Yang; Jie Lu; Yuan-Li Mao
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 7.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

8.  Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody.

Authors:  Takashi Himoto; Seiji Nakai; Fumihiko Kinekawa; Hirohito Yoneyama; Akihiro Deguchi; Kazutaka Kurokochi; Tsutomu Masaki; Shoichi Senda; Reiji Haba; Seishiro Watanabe; Mikio Nishioka; Shigeki Kuriyama
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

9.  Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.

Authors:  Ren-Wen Zhang; Cui-Ping Shao; Na Huo; Min-Ran Li; Hong-Li Xi; Min Yu; Xiao-Yuan Xu
Journal:  World J Gastroenterol       Date:  2015-09-07       Impact factor: 5.742

10.  Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Authors:  Laura M Stinton; Robert P Myers; Carla S Coffin; Marvin J Fritzler
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.